| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 03/18/2004 | US20040054183 Thienopyridine derivatives, their production and use |
| 03/18/2004 | US20040054182 Antiinflammatory agents; rheumatic diseases; antiallergens; skin disorders; anticancer agents; antidiabetic agents |
| 03/18/2004 | US20040054180 Kinase inhibitors; antiinflammatory agents; respiratory system disorders; cardiovascular disorders; antidiabetic agents |
| 03/18/2004 | US20040054179 Antiallergens; skin disorders; antitumor agents; tyrosine kinase inhibitor |
| 03/18/2004 | US20040054172 Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids |
| 03/18/2004 | US20040054155 Oligonucleotide compositions with enhanced efficiency |
| 03/18/2004 | US20040054149 Modified proteolytic enzyme for treatment of osteoarthritis |
| 03/18/2004 | US20040054145 Truncated cd200 |
| 03/18/2004 | US20040054143 Vegf peptides and their use for inhibiting angiogenesis |
| 03/18/2004 | US20040054136 Comprises nucleotide sequences coding transporter associated with antigen processing-like polypeptides (human TAP-like) for diagnosis and treatment of infection, tumors and autoimmune diseases |
| 03/18/2004 | US20040054005 Sodium channel blocker compositions and the use thereof |
| 03/18/2004 | US20040053993 Compositions of tocol-soluble therapeutics |
| 03/18/2004 | US20040053983 1, 2, 4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase |
| 03/18/2004 | US20040053982 Such as 3-(2-(6-methyl-pyridin-2-ylamino)-5-(1,2,4)triazol-1-yl-thiazol-4 -yl)benzonitrile for treatment of inflammatory or obstrucive airways diseases |
| 03/18/2004 | US20040053976 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 03/18/2004 | US20040053964 N-type calcium channel antagonists for the treatment of pain |
| 03/18/2004 | US20040053959 Novel processes and intermediates for preparing triazolo-pyridines |
| 03/18/2004 | US20040053957 Enzyme inhibitors of the I kappa B kinase, therapeutic treatment of autoimmune diseases, inflammatory diseases and cancer; chemical intermediates, sulfiding, sulfonation, desulfonation, cyclization |
| 03/18/2004 | US20040053955 An immunosuppressants for treating allograft rejection, transplant rejection, psoriasis, and rheumatoid arthritis, a 9,10-dihydro-9-oxo-acridine-3-yl- derivatives |
| 03/18/2004 | US20040053953 Treatment of chemokine mediated diseases |
| 03/18/2004 | US20040053952 Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| 03/18/2004 | US20040053949 Protein kinase c inhibitors; antiinflammatory agents; immunosuppresants; antidiabetic agents; immunomodulators |
| 03/18/2004 | US20040053947 Pyrrolo[2,3-D]pyrimidine compounds |
| 03/18/2004 | US20040053944 Antiprotozoa agents; 4-pyrrolidine pyrrolo(3,2-d)pyrimidine and 4-pyrrolidine pyrazolo(4,3-d)pyrimidine derivatives |
| 03/18/2004 | US20040053942 Fused pyrazole derivatives bieng protein kinase inhibitors |
| 03/18/2004 | US20040053941 Substituted pyrazine derivatives |
| 03/18/2004 | US20040053937 Pyrimidine compounds |
| 03/18/2004 | US20040053931 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors |
| 03/18/2004 | US20040053926 Triazine compounds |
| 03/18/2004 | US20040053925 Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use |
| 03/18/2004 | US20040053921 Compounds useful as reversible inhibitors of cysteine proteases |
| 03/18/2004 | US20040053920 Administering to a patient suffering from caspase mediated diseses, an effective amount of a mono,bi or tri-heterocyclic ring containing nitrogen atom attached to ester or thioester to form carbamate group, as caspase inhibitor |
| 03/18/2004 | US20040053917 Reacting cyanophenyl-4-sulfonylchloride with a piperidine-4-oxo in presence of ethylene glycol to form an intermediate, reducing cyano group, followed by amidation, then reacting with an amine to form sulfonamide end |
| 03/18/2004 | US20040053914 Substituted piperzino-pyridine compound, useful for treting pain, anxiety, urinary incontinence, an addictive disorder, Parkinson's disease, epilepsy, psychosis, and used as Selective antagonists of the metabotropic glutamate receptor 5 |
| 03/18/2004 | US20040053908 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective |
| 03/18/2004 | US20040053898 For organ specific therapy; for treatment of menopausal symptoms, hormone-deficiency diseases and neurodegenerative diseases |
| 03/18/2004 | US20040053890 Naphthalene derivatives |
| 03/18/2004 | US20040053885 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
| 03/18/2004 | US20040053884 Comprises N-acylated hydroxyproline derivatives and glycosaminoglycans (chondroitin sulfate); for treatment of arthritis |
| 03/18/2004 | US20040053873 Electroporation methods for introducing bioactive agents into cells |
| 03/18/2004 | US20040053845 Modified peptides as therapeutic agents |
| 03/18/2004 | US20040053842 Cholesterol ester transfer protein inhibitors for use in treating atherosclerosis optionally in combination with other antihypertensive agents |
| 03/18/2004 | US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 03/18/2004 | US20040053828 Partial peptide mimetics and methods |
| 03/18/2004 | US20040053820 Histone deacetylase inhibitor |
| 03/18/2004 | US20040053325 Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1) |
| 03/18/2004 | US20040053281 Comprises enzymatic polypeptide associated with fatty acid metabolism for diagnosing, treating and preventing cancer, neurodegenerative, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders |
| 03/18/2004 | US20040053278 Smad6 and uses thereof |
| 03/18/2004 | US20040052873 Bioavailability / bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 03/18/2004 | US20040052872 Comprises powder containing ash resulting from Symphytum officinale roots calcination in distilled water, with lidocaine for intramuscular administration; for treatment of autoimmune diseases |
| 03/18/2004 | US20040052870 Cyclooxygenase (COX-2) inhibitors; for treatment/prevention of inflammation; nutraceuticals; for treatment of nervous system disorders |
| 03/18/2004 | US20040052869 Orally ingestible preparation of mistletoe lectins and method |
| 03/18/2004 | US20040052732 Synergistic mixture of antiserotonine agents and glucocorticoids; inhalation |
| 03/18/2004 | US20040052729 Immobilization carbohydrates; calibration; diagnosis; antiinflammatory agents, bactericides |
| 03/18/2004 | DE10130985B4 Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente A method for the diagnosis of sepsis and severe infections by determining soluble cytokeratin-1 fragments |
| 03/18/2004 | CA2498297A1 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | CA2497836A1 A method of modulating endothelial cell activity |
| 03/18/2004 | CA2497464A1 A therapeutic agent for improving hypogastric and/or perineal pains |
| 03/18/2004 | CA2497335A1 Formulation for funnelling nucleic acids into eukaryotic cells |
| 03/18/2004 | CA2495284A1 Diarylurea derivatives and their use as chloride channel blockers |
| 03/18/2004 | CA2493974A1 Pharmaceutical dosage form comprising a sulfite compound |
| 03/17/2004 | EP1398326A2 Monoclonal antibodies against recombinant stratum corneum chymotryptic enzyme (SCCE) |
| 03/17/2004 | EP1398315A1 Anti-inflammatory oxo-derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use |
| 03/17/2004 | EP1398313A1 Novel heterocyclic derivatives and medicinal use thereof |
| 03/17/2004 | EP1398036A1 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 03/17/2004 | EP1398033A2 Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis |
| 03/17/2004 | EP1398025A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein |
| 03/17/2004 | EP1397683A2 Methods for identifying compounds for treatment of ibd |
| 03/17/2004 | EP1397507A1 Methods and compositions for treating cardiovascular disease using 10218 |
| 03/17/2004 | EP1397484A2 Methods and products related to fgf dimerization |
| 03/17/2004 | EP1397374A2 Siglec inhibitors |
| 03/17/2004 | EP1397365A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 03/17/2004 | EP1397364A1 Novel pyrrole derivatives as pharmaceutical agents |
| 03/17/2004 | EP1397363A1 5-ethyl-imidazotriazinones |
| 03/17/2004 | EP1397361A1 Carboline derivatives as pdev inhibitors |
| 03/17/2004 | EP1397360A1 Azaindoles |
| 03/17/2004 | EP1397359A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 03/17/2004 | EP1397357A2 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 03/17/2004 | EP1397356A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 03/17/2004 | EP1397355A1 Pyridyl cyanoguanidine compounds |
| 03/17/2004 | EP1397340A2 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 03/17/2004 | EP1397172A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397170A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397153A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 03/17/2004 | EP1397142A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 03/17/2004 | EP1397140A2 Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways |
| 03/17/2004 | EP1397137A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP1397135A2 Combination of a pde4 inhibitor and tiotropium or derivative thereof for treating obstructive airways |
| 03/17/2004 | EP1397134A2 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways |
| 03/17/2004 | EP1397105A1 Methods for inhibiting angiogenesis |
| 03/17/2004 | EP1242406B1 Novel compounds |
| 03/17/2004 | EP1242364B1 Adamantane derivatives |
| 03/17/2004 | EP1224175B1 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 03/17/2004 | EP1147102B1 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 03/17/2004 | EP1144365B1 Inhibitors of alpha-4 beta-1 mediated cell adhesion |
| 03/17/2004 | EP1140936B1 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 03/17/2004 | EP1100792B1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP0971588B1 Novel cannabinoid receptor modulators |
| 03/17/2004 | EP0915974B1 Modified tie-2-receptor ligands |
| 03/17/2004 | EP0891362B1 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |